ATAI Life Sciences N.V’s recent filing unveils that its Officer SAHIL KIRPEKAR acquired Company’s shares for reported $0.2 million on Jun 04 ’25. In the deal valued at $2.48 per share,80,000 shares were bought.
Then, Kirpekar Sahil sold 48,563 shares, generating $65,560 in total proceeds. Upon selling the shares at $1.35, the Chief Business Officer now owns 115,636 shares.
Before that, Craig Kevin James sold 11,563 shares. ATAI Life Sciences N.V shares valued at $15,610 were divested by the Chief Medical Officer at a price of $1.35 per share. As a result of the transaction, Craig Kevin James now holds 8,437 shares, worth roughly $17802.07.
H.C. Wainwright reiterated its ATAI Life Sciences N.V [ATAI] rating to a Buy in a research note published on November 18, 2024; the price target was $10. A number of analysts have revised their coverage, including Maxim Group’s analysts, who increased its forecast for the stock in early April from “a Hold” to “a Buy”. Loop Capital began covering ATAI with “Buy” recommendation on November 01, 2022. Maxim Group started covering the stock on November 30, 2021. It rated ATAI as “a Buy”.
Price Performance Review of ATAI
On Friday, ATAI Life Sciences N.V [NASDAQ:ATAI] saw its stock fall -3.21% to $2.11. Over the last five days, the stock has lost -12.45%. ATAI Life Sciences N.V shares have risen nearly 58.65% since the year began. Nevertheless, the stocks have risen 59.85% over the past one year. While a 52-week high of $2.64 was reached on 06/02/25, a 52-week low of $1.03 was recorded on 04/09/25.
Levels Of Support And Resistance For ATAI Stock
The 24-hour chart illustrates a support level at 2.05, which if violated will result in even more drops to 2.00. On the upside, there is a resistance level at 2.17. A further resistance level may holdings at 2.24.
How much short interest is there in ATAI Life Sciences N.V?
A steep rise in short interest was recorded in ATAI Life Sciences N.V stocks on 2025-05-30, dropping by -0.65 million shares to a total of 11.55 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 12.19 million shares. There was a decline of -5.59%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 11, 2021 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
